Cara Therapeutics to Present at Multiple Upcoming Investor Conferences
November 11 2020 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, or KORs, today announced that
Derek Chalmers, Ph.D., D.Sc., President and Chief Executive
Officer, will participate in the following upcoming virtual
investor conferences and events in November and December:
Stifel 2020 Virtual Healthcare
Conference, November 16, 2020 – November
18, 2020Fireside Chat on Monday, November 16, 2020
at 8:40 a.m. ET
Jefferies Virtual London Healthcare
Conference, November 17, 2020 – November 19,
2020Fireside Chat on Thursday, November 19, 2020 at 9:40
a.m. ET
Piper Sandler Virtual Healthcare
Conference, December 1, 2020 – December 3,
2020Pre-recorded Fireside Chat Available on Monday,
November 23, 2020 at 10:00 a.m. ET
Webcasts of the fireside chats can be accessed
under "Events & Presentations" in the News & Investors
section of the Company's website at www.CaraTherapeutics.com.
Archived webcast recordings will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. In two Phase 3 trials, KORSUVA Injection has
demonstrated statistically significant reductions in itch intensity
and concomitant improvement in quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP). Cara has successfully
completed its Phase 2 trial of Oral KORSUVA for the treatment of
pruritus in patients with CKD and is currently conducting Phase 2
trials of Oral KORSUVA in atopic dermatitis and primary biliary
cholangitis patients with moderate-to-severe pruritus.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:Janhavi MohiteStern Investor
Relations, Inc.212-362-1200 janhavi.mohite@SternIR.com
MEDIA CONTACT:Annie Starr6 Degrees973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2024 to May 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From May 2023 to May 2024